Skip to main content

Enigma Diagnostics Licenses Rights to ABI's '907 Real-Time PCR Patent

NEW YORK (GenomeWeb News) – UK molecular diagnostics company Enigma Diagnostics said today that it has licensed access to an Applied Biosystems patent for real-time detection of nucleic acid amplification products.
 
The Porton Down, UK-based company, which specializes in decentralized and point-of-care diagnostics, said it has licensed access to US Patent No. 5,928,907, “System for real time detection of nucleic acid amplification products.”
 
Enigma said that it is the third license agreement it has signed with ABI and that the technology complements its license under other patents owned by Applied Biosystems for real-time PCR thermal cyclers.
 
Enigma also said that this is the first license ABI has granted to the methods claimed under the ‘907 patent.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.